Literature DB >> 15897561

Distinct methylation patterns of benign and malignant liver tumors revealed by quantitative methylation profiling.

Ulrich Lehmann1, Ina Berg-Ribbe, Luzie U Wingen, Kai Brakensiek, Thomas Becker, Jürgen Klempnauer, Brigitte Schlegelberger, Hans Kreipe, Peer Flemming.   

Abstract

PURPOSE: A comparative quantitative methylation profiling of hepatocellular carcinoma and the most frequent benign liver tumor, hepatocellular adenoma, was set up for the identification of tumor-specific methylation patterns. EXPERIMENTAL
DESIGN: The quantitative methylation levels of nine genes (RASSF1A, cyclinD2, p16INK4a, DAP-K, APC, RIZ-1, HIN-1, GSTpi1, SOCS-1) were analyzed in hepatocellular carcinoma and adjacent normal tissue (n = 41), hepatocellular adenoma and adjacent normal tissue (n = 26), focal nodular hyperplasia (n = 10), and unrelated normal liver tissue (n = 28). Accumulated methylation data were analyzed using various statistical algorithms, including hierarchical clustering, to detect tumor-specific methylation patterns.
RESULTS: Cluster analysis revealed that hepatocellular adenoma displays a methylation profile much more similar to that found in normal liver tissue and focal nodular hyperplasia than to that found in hepatocellular carcinoma. Many characteristic differences were not detected when using mere qualitative methylation assays. The cyclinD2 gene was identified as a new and frequent target for aberrant hypermethylation in hepatocellular carcinoma (68%). In the control group of 28 liver specimens from healthy donors, a clear correlation between age of patient and frequency and level of aberrant methylation was seen, which could not be detected in the group of hepatocellular carcinoma specimens.
CONCLUSIONS: Methylation profiling can clearly contribute to the unequivocal classification of suspicious lesions, but only if done in a quantitative manner applying cell type and gene-specific thresholds. In hepatocellular carcinoma, the altered methylation patterns accompanying malignant transformation override the age-dependent increase in gene methylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15897561     DOI: 10.1158/1078-0432.CCR-04-2462

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  29 in total

1.  Silence of HIN-1 expression through methylation of its gene promoter in gastric cancer.

Authors:  Yan Gong; Ming-Zhou Guo; Zhi-Jia Ye; Xiu-Li Zhang; Yong-Liang Zhao; Yun-Sheng Yang
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Rapid identification of promoter hypermethylation in hepatocellular carcinoma by pyrosequencing of etiologically homogeneous sample pools.

Authors:  Emelyne Dejeux; Virginie Audard; Catherine Cavard; Ivo Glynne Gut; Benoit Terris; Jörg Tost
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

Review 3.  [Hepatocellular adenoma. Malignancy potential and differentiation from hepatocellular carcinoma].

Authors:  P Flemming; U Lehmann; D Steinemann; H Kreipe; L Wilkens
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

Review 4.  [Liver resection and transplantation for hepatic tumors].

Authors:  H Lang; C E Broelsch
Journal:  Internist (Berl)       Date:  2007-01       Impact factor: 0.743

5.  Comparative analysis of promoter methylation and gene expression endpoints between tumorous and non-tumorous tissues from HCV-positive patients with hepatocellular carcinoma.

Authors:  Eric J Formeister; Masato Tsuchiya; Hideki Fujii; Svitlana Shpyleva; Igor P Pogribny; Ivan Rusyn
Journal:  Mutat Res       Date:  2010-08-22       Impact factor: 2.433

6.  Differential methylation of the promoter and first exon of the RASSF1A gene in hepatocarcinogenesis.

Authors:  Surbhi Jain; Lijia Xie; Batbold Boldbaatar; Selena Y Lin; James P Hamilton; Stephen J Meltzer; Shun-Hua Chen; Chi-Tan Hu; Timothy M Block; Wei Song; Ying-Hsiu Su
Journal:  Hepatol Res       Date:  2014-12-09       Impact factor: 4.288

7.  Frequent and distinct aberrations of DNA methylation patterns in fibrolamellar carcinoma of the liver.

Authors:  Wolfgang Tränkenschuh; Florian Puls; Matthias Christgen; Cord Albat; Albert Heim; Jeanette Poczkaj; Peer Fleming; Hans Kreipe; Ulrich Lehmann
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

8.  DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection.

Authors:  Qinghua Feng; Joshua E Stern; Stephen E Hawes; Hiep Lu; Mingjun Jiang; Nancy B Kiviat
Journal:  Exp Mol Pathol       Date:  2010-01-14       Impact factor: 3.362

9.  HIN-1: a New Epigenetic Biomarker Crucial for Therapy Selection in Glioblastoma Multiforme.

Authors:  M Herranz; M E Padín-Iruegas; Nieves Martínez-Lago; S Aguín Losada; P Raña-Díez; E Brozos Vázquez; J J Carrera; J R Antúnez; A Ruibal; R López-López
Journal:  Mol Neurobiol       Date:  2015-03-11       Impact factor: 5.590

10.  APC promoter methylation and protein expression in hepatocellular carcinoma.

Authors:  Antal Csepregi; Christoph Röcken; Juliane Hoffmann; Ping Gu; Stephan Saliger; Oliver Müller; Regine Schneider-Stock; Nadine Kutzner; Albert Roessner; Peter Malfertheiner; Matthias P A Ebert
Journal:  J Cancer Res Clin Oncol       Date:  2007-11-01       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.